Compare Adaptive Biotechnologies Corp (ADPT) vs Amplify Cybersecurity ETF (HACK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amplify Cybersecurity ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.93 (market cap $3.33B), while Amplify Cybersecurity ETF trades at $107.5. The key difference: Amplify Cybersecurity ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | HACK | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $110.27 |
52-Week Low | $10.24 | $70.69 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HACK trades at $110.27, up 3.08% with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF benefits from growing sector spending exceeding $300 billion in 2026, with recent partnerships expanding market reach. Technical indicators show strong trend strength while oscillators suggest potential near-term consolidation.
The outlook remains positive given cybersecurity's essential role in AI adoption, though elevated RSI levels indicate near-term overbought conditions. Key risks include sector competition and market volatility, while institutional momentum supports continued growth potential in the expanding cybersecurity market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →
